All Drug Targets articles
-
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
-
NewsMetabolic vulnerabilities identified in rare Fibrolamellar liver cancer
Researchers have identified metabolic vulnerabilities in Fibrolamellar cancer, a rare liver malignancy affecting adolescents and young adults, using functional profiling and mass spectrometry. The findings suggest chemotherapy-resistant tumours may be susceptible to metabolism-targeted therapies.
-
NewsAI platform identifies novel gp130 inhibitor for colorectal cancer
An AI-assisted drug discovery platform using transfer learning has identified a promising gp130 inhibitor for colorectal cancer.
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
NewsCholesterol trafficking disruption targets TP53-mutant cancers
Scientists have identified a mechanism to starve aggressive cancers by blocking cholesterol transport within tumour cells, offering a targeted approach for malignancies carrying TP53 mutations, present in half of all cancers.
-
NewsStudy reveals how GLP-1 drugs trigger weight loss in brain cells
NIH researchers have identified the intracellular signalling pathways through which semaglutide and other GLP-1 receptor agonists induce weight loss, revealing why patient responses vary and treatment effects plateau over time.
-
ArticleTurning GWAS signals into drug targets with scalable CRISPR
Genome-wide association studies have linked thousands of genetic variants to disease, yet most remain disconnected from drug-relevant biology. Neville Sanjana, Professor at New York University and Core Faculty Member at the New York Genome Center, explains how scalable CRISPR screens systematically link noncoding variants to causal genes and therapeutic targets.
-
NewsPERM1 protein linked to heart recovery in LVAD patients
A newly identified protein may explain why some failing hearts recover function following mechanical support while others do not.
-
NewsNew study indentifies Golgi apparatus proteins as cancer growth drivers
Researchers at the Harrington Discovery Institute have identified cellular mechanisms involving Golgi apparatus proteins that drive cancer progression by trafficking growth factor receptors to cell surfaces.
-
ArticleAACR 2026 part 1: AI design, precision biology and the next wave of oncology innovation
At AACR 2026, industry leaders discussed how oncology R&D is moving beyond isolated technological advances towards integrated discovery systems.
-
NewsOutSee wins Longitude Prize award for ALS target discovery
OutSee has secured a Discovery Award from the Longitude Prize on ALS, providing £100,000 in funding and access to genomic data from 9,000 patients. The company will deploy its AI-driven Nomaly platform to identify novel therapeutic targets for amyotrophic lateral sclerosis over a nine-month research programme.
-
NewsRAGE receptor identified as key driver of age-related metastasis
Georgetown Lombardi researchers have identified RAGE, an inflammatory receptor, as a key mediator of age-related breast cancer metastasis.
-
NewsMYC protein found to repair DNA in cancer cells
Oregon Health & Science University researchers have identified a non-canonical function of the MYC oncoprotein in DNA damage repair, revealing how tumour cells survive chemotherapy-induced stress.
-
NewsMitochondrial fission activation offers new tool in fight against antibiotic resistance
Scientists at The University of Queensland have discovered that activating mitochondrial fission can enhance immune defences against antibiotic-resistant bacteria.
-
NewsCAR T cell therapy eliminates glioblastoma tumours in preclinical study
A next-generation CAR T cell immunotherapy targeting the urokinase receptor has eliminated treatment-resistant glioblastoma tumours in preclinical models.
-
NewsNew malaria drug T111 targets all parasite stages in single treatment
A novel compound developed over 15 years of research has demonstrated unprecedented activity against liver, blood and sexual stages of Plasmodium parasites, possibly positioning it as a potential cure for malaria.
-
NewsMolecular switch discovery could lead to new bone disease treatments
A molecular switch that activates an alternative energy-burning pathway in brown fat has been identified by McGill University researchers, offering potential new approaches to treating bone disease and metabolic disorders through the TNAP enzyme’s glycerol pocket.
-
NewsYAP1 protein found to drive chemotherapy resistance in small cell lung cancer after treatment
University of Texas MD Anderson Cancer Center researchers have discovered that YAP1 protein expression emerges after chemotherapy treatment in small cell lung cancer, enabling resistant cancer cells to survive and proliferate.
-
NewsProtein modifications control drug binding and efficacy in new study
New research reveals that subtle chemical changes to proteins after synthesis play a critical role in determining drug-protein interactions.
-
ArticleTurning CRISPR hits into confident drug discovery decisions
Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman Tamaddon-Jahromi, a postdoctoral research associate at the University of Cambridge, discusses how end-to-end CRISPR screening strategies, iPSC-derived neuronal models and layered quality control can convert functional genomics signals into actionable therapeutic hypotheses.